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Extended-spectrum b-lactamases (ESBL) confer resistance to
aztreonam, cefotaxime, ceftazidime and related oxyimino-b-
lactams, but are unable to hydrolyze cephamycins or carba-
penems. Each ESBL may confer universal resistance to these
oxyimino-compounds or selective resistance for particular b-
lactams. In most instances, ESBL enzymes are inhibitable by
clavulanate or other inhibitors such as tazobactam or sulbactam.
ESBLs have rapidly established a global presence and, once
established in a region, often become a prominent resistance
mechanism. Within 5 years of detection of the first ESBL in
France, the overall prevalence of ESBL-producing Klebsiella
pneumoniae increased to 14% and in certain hospitals the preva-
lence surpassed 35% [1]. Today, hospital outbreaks of ESBL-
producing K. pneumoniae have been described from many coun-
tries and, in particular regions, the prevalence of these organisms
has exceeded 40–50% [2,3]. Epidemiologic studies including
molecular typing methods have revealed clonal spread within
hospitals as well as interhospital transmission of extended-spec-
trum b-lactam-resistant K. pneumoniae [3,4]. In addition, plas-
mids carrying ESBL genes have been spread between bacterial
species and to genetically unrelated Klebsiella isolates [5].
More recently, K. pneumoniae and Escherichia coli isolates have
acquired plasmid-mediated AmpC b-lactamases [6–8]. These
enzymes are constitutively expressed at high levels and confer
resistance to the cephamycins as well as the extended-spectrum
cephalosporins.
In this study, we have characterized the antimicrobial pheno-
types, molecular epidemiology and the general patterns of b-
lactamases expressed by a series of ESBL-producing K. pneu-
moniae isolates obtained from six Russian medical centres.
Thirty-one K. pneumoniae isolates were collected from six Rus-
sian medical centres during 1994–96. The organisms were iso-
lated from blood, cerebrospinal fluid, urine, sputum and
wounds. Isolates were selected on the basis of intermediate or
resistant minimum inhibitory concentrations (MICs) to third
generation cephalosporins. Seventeen strains came from one
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medical centre (Medical Center 1, Table 1). Strains labelled
‘A’ were isolated between September and October, 1994; ‘B’
isolates from September, 1995 to January 1996; and the single
‘C’ strain was isolated in late March 1996. Other medical centres
(Medical Centers 2–6) were located in cities ranging from
Western Russia to Siberia.
The MICs were determined by broth microdilution and E-
test methodologies (AB Biodisk, Solna, Sweden) as per the
1998 National Committee for Clinical Laboratory Standards
(NCCLS) recommendations. All isolates demonstrated an
ESBL phenotype using double-disk synergy [9]. Additionally,
ESBL phenotypes were characterized with ESBL E-test strips
containing 0.016 to 256 mg/L of ceftazidime, cefuroxime,
cefotaxime, ceftriaxone or cefepime in the presence of a fixed
concentration of clavulanic acid (2 mg/L, generously provided
by AB Biodisk) (see Table 1). Each isolate was evaluated for
evidence of a eight-fold or greater decrease in MIC to one or
more oxyimino-cephalosporins [10]. Cefotaxime, ceftriaxone
and cefepime detected 100% of the ESBLs whereas ceftazidime
detected 97% and cefuroxime detected only 81% of ESBL
phenotypes. The currently marketed ceftazidime E-test strip
would have missed only one isolate (organism 26; Table 1).
This organism had a ceftazidime MIC of 2 mg/L that dropped
to 1 mg/L in the presence of clavulanic acid.
Typically, the genes for ESBLs reside on large plasmids which
also carry resistance genes for other classes of antimicrobials
[11,12]. Indeed, it has been suggested that multidrug resistance
in enteric Gram-negative isolates should instigate further testing
for ESBLs [11,13]. The Russian isolates demonstrated co-resist-
ances to tobramycin or gentamicin (97%), trimethoprim–sulfa-
methoxazale (84%) and tetracycline (68%) (Table 1). Fluoro-
quinolone resistance among the Russian isolates was rare (3%),
probably reflecting the fact that quinolone resistance is most
commonly acquired through chromosomal mutations rather
than plasmid exchange. In most cases, high level fluo-
roquinolone resistance results from chromosomal mutations in
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the gyr A and par C genes or changes in permeability or efflux
which reflect selective pressure in the clinical environment
[14]. Only one study has demonstrated low-level quinolone
resistance transmitted on plasmid DNA [15].
To determine whether clonal spread of organisms carrying an
ESBL was common in Russia, genotype analysis was performed
using pulsed-field gel electrophoresis (PFGE) of SpeI-digested
chromosomal DNA (Table 1 and Figure 1). Genomic DNA
was isolated and digested with Spe1 (New England Biolabs,
Beverly, MA, USA) as previously described [16]. Electro-
phoresis was performed on the CHEF-DRII (Bio-Rad Lab-
oratories, Richmond, CA, USA) with the following conditions:
0.5  TBE, 1% Agarose, 13 °C, 200 V, 23 h with the switch
interval at 5 to 60 s. Gels were stained with ethidium bromide.
Strains that contained restriction fragment patterns that differed
by more than three bands were considered unique and were
assigned a letter designation. If banding patterns differed by
three bands or less, an alpha numeric designation was assigned
to each minor subtype (e.g. A1, A2, etc.) [17].
Figure 1 Pulsed-field gel electrophoresis (PFGE) of selected K. neumoniae isolates. Genomic DNA was digested with SpeI and electrophoresed
on a 1% agarose gel. Genomic DNA from Staphylococcus aureus (NCTC 8325) digested with SmaI served as the molecular weight standard.
Strains which contained restriction fragments which differed by more than three bands were considered unique and have been assigned a
different letter. Isolates which have a PFGE pattern which includes a letter and number, represent highly related strains which differed by less
than three bands (subtypes). All isolates were analyzed by PFGE and the results are summarized in Table 1.
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Thirteen of 17 isolates that came from Medical Center 1
were highly related by PFGE. Although there were six PFGE
subtypes (G1-G6) among these 13 isolates, none of the patterns
differed by more than three bands. Of the remaining four
organisms isolated at Medical Center 1, two were identical by
PFGE analysis and the remaining organisms represented single
molecular types. Similarly, organisms isolated from each of
the five remaining medical centres showed a high degree of
molecular relatedness (Table 1). With the exception of Medical
Center 4, all isolates within each medical centre showed highly
related PFGE patterns whereas Medical Center 4 contributed
three organisms, two of which demonstrated identical PFGE.
These results suggest that there was significant clonal trans-
mission within each institution. However, there was no evi-
dence for clonal spread between medical centers. Medical
Center 1 continued to identify clonal isolates over 18 months.
Unfortunately, this experience is not uncommon. A number
of hospitals have identified the prolonged endemic or epidemic
presence of K. pneumoniae isolates carrying ESBLs [18].
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The ISO-electric focussing (IEF) analysis of b-lactamases
carried by organisms can provide indications that help place
enzymes into the Bush–Jacoby–Medeiros functional group 2be
enzyme class or other enzyme classes such as, the plasmid-
mediated Amp-C-like enzymes Bush–Jacoby–Medeiros func-
tional group 1 [19]. Although IEF alone cannot differentiate
specific b-lactamases, it does provide a rapid method to assess
the relative nature of b-lactamases present in a particular organ-
ism and a means for comparison of b-lactamases present in
different organisms.
Crude b-lactamase extracts were prepared by freeze–thaw
lysis of bacterial cultures grown exponentially in tryptic soy
broth, as previously described [20]. Analytical isoelectric focus-
ing was performed using a Multiphore II electrophoresis system
and prepared ampholine-polyacrylamide plates, pI 3.5–9.5 and
pI 5.5–8.5 (Amersham Pharmacia Biotech, Piscataway, NJ,
USA) with limits of 1500 V, 30 mA, 30 W for 1.5 h or 1600 V,
50 mA, 25 W for 2.5 h, respectively. The b-lactamase activity
was detected with nitrocephin 500 mg/L (Beckton Dickinson
Microbiology Systems, Cockeysville, MD, USA). TEM 1,
TEM 4, SHV 1, SHV 3, and SHV 5 b-lactamases expressed in
E. coli C600 (generously provided by G. Jacoby) were used as
pI standards [21]. Known pI values of each standard were
plotted against the distance from the cathode and a regression
analysis was performed (Microsoft, Redmond, WA, USA,
Excel 98). Unknown b-lactamase pIs were calculated using the
regression curve generated from each gel. Crude lysates were
also analyzed for cefoxitin-inhibitable b-lactamases typical of
the AmpC or Bush–Jacoby–Medeiros functional Class 1
enzymes [20]. These gels were developed with a mixture of
nitrocephin (500 mg/L) and cefoxitin (5000 mg/L) [6].
The IEF analysis of the b-lactamases provided some expla-
nation for the complexity of antimicrobial resistance in these
Russian isolates. Most isolates contained two or more b-lac-
tamases (Table 1 and Figure 2) with a range between one and
four b-lactamases per isolate. The b-lactam susceptibilities
probably reflect additivity among these multiple enzymes.
Twenty isolates (65%) expressed a b-lactamase that comigrated
with TEM1 at pI 5.4. This number closely resembles French
studies where 66% of ESBL-expressing K. pneumoniae isolates
carried TEM1 [22]. This coexpression of TEM1 and an ESBL
can significantly compromise the effects of b-lactamase inhibitors
potentially resulting in significant therapeutic consequences [23].
Isolates from a single medical centre typically displayed b-
lactamases with shared pIs. Some of these enzymes appeared to
be unique for a particular medical centre. For example, Medical
Center 3 contained a b-lactamase, pI 7.2, which was seen only
within this medical centre and was shared by all isolates analyzed
from this hospital. Medical Center 6 demonstrated three
organisms with identical IEF profiles yet, two different PFGE
patterns suggesting plasmid dissemination within this hospital
as well as clonal transmission.
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Twenty-seven strains expressed one or more ESBLs that
comigrated at a pI of 7.6. Since several SHV ESBL variants
(SHV 2,2a, 6, 7, 8) and the Klebsiella pneumoniae chromosomal
SHV1 enzyme cluster at this pI, it is difficult to determine
whether these isolates contain identical b-lactamases or whether
they express one or more SHV enzymes [24]. In Medical Center
1, the 13 isolates that shared PFGE patterns also shared b-
lactamases with similar pIs (5.4 and 7.6). Interestingly, three
isolates from this group contained only a single b-lactamase of
pI 7.6. The antibiograms from these three organisms differed
markedly from other related strains from the same medical
centre, showing significantly higher MICs for all oxyimino-
cephalosporins and related compounds, as well as cefoxitin.
These three organisms may express an SHV variant better able
to hydrolyze extended-spectrum cephalosporins. Alternatively,
differences in antimicrobial susceptibilities may reflect dif-
ferences in promoter strength, plasmid number or permeability
differences among these isolates [25,26]. Sequence analysis and
further molecular studies will be required to determine the
exact nature of antimicrobial resistances in these isolates.
Seven isolates from three different medical centres expressed
b-lactamases with highly basic pIs of 8.5–8.8. This pI range
often includes enzymes from the Amp-C or functional class 1
family [20]. To determine whether these highly basic enzymes
were inhibited by cefoxitin, IEF gels were developed with
nitrocephin 500 mg/L or nitrocephin plus cefoxitin
(5000 mg/L). All enzymes comigrating at 8.5 and 8.8 were
inhibited by cefoxitin. However, only two of these isolates
expressed intermediate MICs (16 mg/L) to cefoxitin. Although
derepressed AmpC enzymes typically confer high-level cefox-
itin resistance, low levels of expression of these enzymes can
lead to lower cefoxitin MICs. The Russian isolates containing
these highly basic, cefoxitin-inhibitable b-lactamases may
express only low levels of an AmpC enzyme. Alternatively,
these enzymes may represent another class of b-lactamase that
hydrolzes cefoxitin at low levels. Conjugation and sequence
analysis experiments will be required to further identify these
enzymes.
This study was not designed to address prevalence or to
identify all organisms carrying ESBLs. However, in 1996, 33%
of 168 isolated nosocomial strains of K. pneumoniae from Rus-
sian intensive care units (ICU) demonstrated an elevated MIC
for third-generation cephalosporins and an ESBL phenotype.
Within each ICU the percentages of K. pneumoniae expressing
an ESBL phenotype ranged from 29 to 83% (L. Stratcounski
and O. Stetsiouk, unpublished data). These numbers are high,
but not unprecedented. The literature demonstrates many cases
where hospitals have noted rapid increases in the numbers of
organisms carrying ESBLs, interunit spread through each
hospital and interhospital spread to neighbouring hospitals and
nursing care facilities [3,4,9,18,27–29]. It is clear that identi-
fication of a single isolate containing an ESBL requires rapid
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Figure 2 Isoelectric focus analysis. Crude b-lactamase extracts were electrophoresed on ampholine-polyacrylamide gels containing a pI range
of 3.5–9.5. b-lactamase activity was detected with nitrocephin. Escherichia coli C-600 strains which expressed TEM1, TEM4, SHV1, SHV3, and
SHV5 served as pI standards. An Enterobacter aerogenes known to produce an Amp C enzyme served as a control for cefoxitin inhibition.
The left half of the panel was developed with nitrocephin alone and the right half of the gel was developed with nitrocephin and cefoxitin.
epidemiologic response including strict infection control mea-
sures and review of antimicrobial use policies.
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Listeriosis is a food-borne disease which occurs at epidemic
or sporadic infections. Neonatal listeriosis is divided into early
onset with manifestations of septicemia whereas meningitis is
most often acquired at late onset [1]. The early-onset form is
